Propanc Biopharma, Inc. PPCB
1.77 USD +0.10 (+6.10%)
At closeNov 6, 2026, 4:00 PM EST
1.70 -0.07 -3.95%
After hours · Nov 6, 4:00 PM ET
1.65 Day range 1.79
1.63 52-week range 315.00
- YTD
- -98.68%
- 1 year
- -99.36%
- Market cap
- 1.83M
- EPS (ttm)
- -176.20
- YTD return
- -98.68%
- 1-year return
- -99.36%
- Volume
- 10.09K
- Avg volume
- 187.44K
- Open
- 1.70
- Previous close
- 1.67
- Day's range
- 1.65 – 1.79
- 52-week range
- 1.63 – 315.00
- Earnings date
- Sep 27, 2023
5D -0.36 (-18.00%)
Next earnings
Sep 27, 2023
Expected Sep 27, 2023. Consensus EPS estimate 0.00.
Financials — quick view
PPCB Revenue — quarterly 0
PPCB Net income — quarterly -4.57M
PPCB EPS — quarterly 62.00
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | 0.00 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -0.01 | — | — |
| Feb 20, 2024 | Dec 1, 2023 | 0.00 | -0.03 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -0.04 | — | — |
| Sep 27, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| May 15, 2023 | Mar 1, 2023 | 0.00 | 0.00 | — | — |
News
Propanc Biopharma Reports Preclinical Data with PRP & PRP plus TGF-β Inhibitor on TGF-β Pathway in Pancreatic Cancer 
Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients 
Propanc Biopharma Continues Clinical Development Program For Propanc Proenzyme; Targets February 2027 For Its First Clinical Site Initiation - Propanc Biopharma Announces New Preclinical Data Supporting Potential Of PRP To Treat Chemotherapy Resistance In Pancreatic Cancer; PRP Monotherapy Reduced Cancer Cell Proliferation By ~50–54% And Suppressed Long-term Clonogenic Survival By Up To 59%
Propanc Biopharma Announces 1-For-10 Reverse Stock Split, Effective Oct. 26 
Propanc Biopharma Announces It Has Identified Pancreatic Proenzyme Formulation As Potential Strategy For Addressing Chemotherapy Resistance In Pancreatic Cancer - Propanc Biopharma Registers Resale Of 6,500,000 Shares Of Common Stock
- Propanc Biopharma Analysis Of PRP Against Clinical Datasets From Erasca Demonstrates PRP Does Not Exhibit RAS
Propanc Biopharma Issues Comparative Analysis Of Lead Candidate PRP Against Clinical Datasets From RAS-Targeted Programs, Including Revolution Medicines’ Daraxonrasib And Erasca’s Pan-RAS Molecular Glue ERAS-0015 
12 Health Care Stocks Moving In Friday's Intraday Session
Your note
Sign in to keep a note on PPCB — it syncs with the Stock Master app.